ACCOUNTS - Final Accounts


Caseware UK (AP4) 2021.0.152 2021.0.152 2021-06-302021-06-3022020-07-01falseNo description of principal activity2truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006. 07673770 2020-07-01 2021-06-30 07673770 2019-07-01 2020-06-30 07673770 2021-06-30 07673770 2020-06-30 07673770 2019-07-01 07673770 c:Director1 2020-07-01 2021-06-30 07673770 d:CurrentFinancialInstruments 2021-06-30 07673770 d:CurrentFinancialInstruments 2020-06-30 07673770 d:CurrentFinancialInstruments d:WithinOneYear 2021-06-30 07673770 d:CurrentFinancialInstruments d:WithinOneYear 2020-06-30 07673770 d:ShareCapital 2021-06-30 07673770 d:ShareCapital 2019-07-01 2020-06-30 07673770 d:ShareCapital 2020-06-30 07673770 d:ShareCapital 2019-07-01 07673770 d:CapitalRedemptionReserve 2021-06-30 07673770 d:CapitalRedemptionReserve 2020-06-30 07673770 d:CapitalRedemptionReserve 2019-07-01 07673770 d:RetainedEarningsAccumulatedLosses 2020-07-01 2021-06-30 07673770 d:RetainedEarningsAccumulatedLosses 2021-06-30 07673770 d:RetainedEarningsAccumulatedLosses 2019-07-01 2020-06-30 07673770 d:RetainedEarningsAccumulatedLosses 2020-06-30 07673770 d:RetainedEarningsAccumulatedLosses 2019-07-01 07673770 c:FRS102 2020-07-01 2021-06-30 07673770 c:AuditExempt-NoAccountantsReport 2020-07-01 2021-06-30 07673770 c:FullAccounts 2020-07-01 2021-06-30 07673770 c:PrivateLimitedCompanyLtd 2020-07-01 2021-06-30 07673770 2 2020-07-01 2021-06-30 iso4217:GBP xbrli:pure

Registered number: 07673770










BIRCHWOOD PHARMA LTD








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 JUNE 2021

 
BIRCHWOOD PHARMA LTD
REGISTERED NUMBER: 07673770

BALANCE SHEET
AS AT 30 JUNE 2021

2021
2020
Note
£
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
8,466
17,287

Cash at bank and in hand
 5 
818,406
838,043

  
826,872
855,330

Creditors: amounts falling due within one year
 6 
(2,745)
(2,583)

Net current assets
  
 
 
824,127
 
 
852,747

Total assets less current liabilities
  
824,127
852,747

  

Net assets
  
824,127
852,747


Capital and reserves
  

Called up share capital 
  
110
110

Capital redemption reserve
  
16
16

Profit and loss account
  
824,001
852,621

  
824,127
852,747


The Directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The Directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 23 February 2022.




John Keith Fisher
Director

The notes on pages 3 to 4 form part of these financial statements.

Page 1

 
BIRCHWOOD PHARMA LTD
 

STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 JUNE 2021


Called up share capital
Capital redemption reserve
Profit and loss account
Total equity

£
£
£
£


At 1 July 2019
126
-
1,013,227
1,013,353


Comprehensive income for the year

Loss for the year
-
-
(58,303)
(58,303)

Purchase of own shares
-
16
(102,303)
(102,287)

Shares redeemed during the year
(16)
-
-
(16)



At 1 July 2020
110
16
852,621
852,747


Comprehensive income for the year

Loss for the year
-
-
(28,620)
(28,620)


Contributions by and distributions to owners


At 30 June 2021
110
16
824,001
824,127


The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
BIRCHWOOD PHARMA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021

1.


General information

Birchwood Pharma Ltd is a Company limited by shares and registered on England & Wales. Its registered office is Regus House, Victory Way, Admirals Park, Crossways, Dartford, Kent DA2 6QD.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.3

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
2.4

Debtors

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.5

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.6

Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.7

Financial instruments

The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2020 - 2).

Page 3

 
BIRCHWOOD PHARMA LTD
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2021

4.


Debtors

2021
2020
£
£


Other debtors
8,348
17,061

Prepayments and accrued income
118
226

8,466
17,287



5.


Cash and cash equivalents

2021
2020
£
£

Cash at bank and in hand
818,406
838,043



6.


Creditors: Amounts falling due within one year

2021
2020
£
£

Trade creditors
95
83

Other creditors
500
500

Accruals and deferred income
2,150
2,000

2,745
2,583



7.


Commitments under operating leases

The Company had no commitments under non-cancellable operating leases at the balance sheet date.


Page 4